好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

The role of the cerebellum in tremor-dominant cervical dystonia
Movement Disorders
S3 - Movement Disorders 1 (2:16 PM-2:24 PM)
003
To evaluate the cerebellum in tremor-dominant subtype of cervical dystonia (CD). 

Cervical dystonia may present with a head tremor manifesting as a jerky “no-no” or “yes-yes” head oscillation. In contrast to the tonic or non-tremor-dominant presentation (nTr-CD), this tremor dominant CD (Tr-CD) has this tremulous or tremor-dominant phenotype (Tr-CD) has been proposed to characterize an “ataxic dystonia” subtype of CD. Our analysis of the longitudinal NIH-funded Dystonia Coalition data showed that Tr-CD is a distinct entity seen in older women with a longer disease duration, with milder dystonia and more severe ataxia. Our study on neurophysiology of eye movements in Tr-CD patients highlighted maladaptive cerebellar outflow, manifesting as impaired saccade adaptation.

Through this study, we sought to study clinical and imaging differences in the cerebellum in patients with tremor- and non-tremor-dominant CD with the hypothesis that the former would demonstrate greater cerebellar disability.

Based on our sample size calculations, Tr-CD patients and age- and sex-matched nTr-CD patients were recruited from the University of Cincinnati Movement disorders clinic in a 1:1 ratio (10 each). All patients underwent the following assessment: Scale for the Assessment and Rating of Ataxia (SARA), Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS), gait variability with using ProtoKinetics Zeno Walkway, and cerebellar volume analysis extracted from brain magnetic resonance imaging (MRI) using a known semi-quantitative scale. 

Tr-CD patients exhibited worse SARA scores (9 vs. 7.5, p=0.03), greater median gait variability index (131 vs. 124, p=0.03) and greater superior vermian atrophy than nTr-CD patients (p=0.01). SARA scores inversely correlated with cerebellar volume in all patients (-0.4, p=0.04).  

Head tremor at onset of CD is a distinct subtype of CD with greater cerebellar disability. Recognition of this subtype is necessary to guide patient treatment, prognosis and future clinical trial efforts. 

Authors/Disclosures
Abhimanyu Mahajan, MD, MHS (University of Cincinnati)
PRESENTER
Dr. Mahajan has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Vima Therapeutics, Inc.. Dr. Mahajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Adaptive Biosciences . Dr. Mahajan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Movement disorders clinical practice. The institution of Dr. Mahajan has received research support from DMRF.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Alberto J. Espay, MD, FAAN (University of Cincinnati) Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Tanabe Pharma America (formerly, Neuroderm). Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Avion. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Amneal. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acorda. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kyowa Kirin. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sunovion. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Herantis Pharma. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Supernus (formerly USWorldMeds). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Acadia. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Synaps Dx. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Bial. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for NeuroDiagnostics, Inc (SYNAPS Dx). Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Intrance Medical Systems, Inc.. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merz. Dr. Espay has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Praxis Precision Medicines. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Citrus Health. Dr. Espay has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AskBio. The institution of Dr. Espay has received research support from NIH. The institution of Dr. Espay has received research support from Michael J Fox Foundation for Parkinson's Research. Dr. Espay has received intellectual property interests from a discovery or technology relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care. Dr. Espay has received publishing royalties from a publication relating to health care.